Surface Oncology Inc.

Surface Oncology Inc. is a clinical-stage immuno-oncology company that was founded in 2014. The company is headquartered in the United States and has recently received a significant $28.90MPost-IPO Equity investment on 20 May 2020 from BVF Partners, EcoR1 Capital, Venrock Healthcare Capital Partners, RS Investments. Surface Oncology is dedicated to leveraging its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) to develop next-generation therapies for cancer patients. The company's focus on the development of a broader, more multi-faceted therapeutic approach represents a significant leap forward in immuno-oncology research. The company's diverse clinical and preclinical pipeline of immune-enhancing antibody candidates targets the innate and adaptive arms of the immune system. This approach is aimed at delivering dramatically different therapies for patients and their families by addressing the limitations of current first-generation immunotherapies. Surface Oncology aims to convert patients’ non-responsive ‘cold’ tumors into immune-active ones by leveraging its deep understanding of TME biology to target factors and cells that suppress the anti-tumor immune response. The company's emphasis on breaking through across all dimensions of its work reflects its commitment to delivering transformative outcomes for cancer patients. In terms of discovery, Surface Oncology utilizes its world-class Scientific Advisory Board (SAB) to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies. This approach generates therapeutic-quality antibodies and unique tools for exploring the biology of the tumor microenvironment. With its strong focus on addressing the limitations of current immunotherapies and a commitment to pushing the boundaries of immuno-oncology research, Surface Oncology is well-positioned to make a significant impact in the treatment of cancer.